A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

May 10, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

May 31, 2026

Conditions
Solid Tumor
Interventions
DRUG

ZG005 Powder for Injection

intravenous infusion(IV), once every 3 weeks

DRUG

Donafenib Tosilate Tablets

The dose groups of Donafenib for dose-exploration stage are set as 0.2g BID, 0.1g BID, and 0.1g QD, oral administration.The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage

Trial Locations (1)

Unknown

RECRUITING

The Second Affiliated Hospital of Army Medical University, Chongqing

All Listed Sponsors
lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY